Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beware copycat probes after Sanofi generics case

This article was originally published in Scrip

Executive Summary

This week's €40.6 million fine against Sanofi could presage further investigations into the legality of techniques used by pharmaceutical companies to protect their franchises from generic competition. However, with the lack of previous cases addressing the specific abuses brought to light in the Sanofi case, the limits of acceptable practice may be hard to define, and the need for companies to tread carefully is complicated by the difficulty in pinning down future interpretations of legality.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts